Novartis CEO mum on Bayer buyout

Novartis says it's not interested in merging with another Big Pharma player--but CEO Daniel Vasella (photo) still won't comment on a rumored takeover of German rival Bayer.

Vasella told a French newspaper that a merger isn't the answer to the company's skyrocketing R&D costs and less-than-skyrocketing revenues. But when asked point-blank about Bayer, he clammed up. Some stock analysts have pooh-poohed the notion of Novartis snapping up Bayer. Others, however, helped fuel the rumors, which have died down a bit lately. Vasella's "no comment" just may stir them up again. 

- read the coverage from Forbes

Related Articles:
Rumor Mill: Novartis may bid for Bayer. Report
Cash-rich Novartis CEO mulls biotech buyouts. Report
Bayer plans to beef up biotech pipeline. Report
Novartis CEO critiques U.S. healthcare. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.